Old Web
English
Sign In
Acemap
>
authorDetail
>
J Throup
J Throup
Bristol-Myers Squibb
Physical therapy
Medicine
Pharmacology
Pharmacokinetics
Tyrosine kinase 2
4
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY
2021
Annals of the Rheumatic Diseases
April W. Armstrong
Melinda Gooderham
Richard Warren
Kim A. Papp
Bruce E. Strober
Diamant Thaçi
E. Colston
J Throup
Sudeep Kundu
Subhashis Banerjee
Andrew Blauvelt
Show All
Source
Cite
Save
Citations (2)
AB0026 SELECTIVE INHIBITION OF TYROSINE KINASE 2 WITH AN ORAL AGENT, BMS-986165, COMPARED WITH JANUS KINASE INHIBITORS
2020
Annals of the Rheumatic Diseases
Anjaneya Chimalakonda
James R. Burke
Lin Cheng
Joann Strnad
Ian M. Catlett
A. Patel
J. Shen
Ihab G. Girgis
S Banerjee
J Throup
Show All
Source
Cite
Save
Citations (0)
P638 BMS-986165, an oral selective tyrosine kinase 2 (TYK2) inhibitor, does not affect the pharmacokinetics of methotrexate in healthy subjects
2019
Journal of Crohns & Colitis
A Chimalakonda
J Jones Iii
R Dockens
J Throup
S Banerjee
I Girgis
Show All
Source
Cite
Save
Citations (0)
P349 Cyclosporine has no clinically meaningful effect on pharmacokinetics (PK) of BMS-986165, an oral selective tyrosine kinase 2 (TYK2) inhibitor, in healthy subjects
2019
Journal of Crohns & Colitis
A Chimalakonda
J Jones Iii
R Dockens
J Throup
S Banerjee
I Girgis
Show All
Source
Cite
Save
Citations (0)
1
map